What is the share price of Wanbury Ltd (WANBURY) today?
The share price of WANBURY as on 30th June 2025 is ₹280.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Wanbury Ltd (WANBURY) share?
The past returns of Wanbury Ltd (WANBURY) share are- Past 1 week: 2.29%
- Past 1 month: -0.45%
- Past 3 months: 19.66%
- Past 6 months: -0.17%
- Past 1 year: 79.52%
- Past 3 years: 332.20%
- Past 5 years: 1059.09%
What are the peers or stocks similar to Wanbury Ltd (WANBURY)?
The peers or stocks similar to Wanbury Ltd (WANBURY) include:What is the market cap of Wanbury Ltd (WANBURY) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Wanbury Ltd (WANBURY) is ₹922.20 Cr as of 30th June 2025.What is the 52 week high and low of Wanbury Ltd (WANBURY) share?
The 52-week high of Wanbury Ltd (WANBURY) is ₹329.70 and the 52-week low is ₹154.01.What is the PE and PB ratio of Wanbury Ltd (WANBURY) stock?
The P/E (price-to-earnings) ratio of Wanbury Ltd (WANBURY) is 30.21. The P/B (price-to-book) ratio is 32.99.Which sector does Wanbury Ltd (WANBURY) belong to?
Wanbury Ltd (WANBURY) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Wanbury Ltd (WANBURY) shares?
You can directly buy Wanbury Ltd (WANBURY) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Wanbury Ltd
WANBURY Share Price
280.501.13% (-3.20)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
WANBURY Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
WANBURY Performance & Key Metrics
WANBURY Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 30.20 | 32.99 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.56 | 6.60 | 0.83% |
WANBURY Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
WANBURY Company Profile
Wanbury Limited is a pharmaceutical company which offers active pharmaceutical ingredient in over 70 countries.
SUNPHARMA
PE Ratio
36.79
36.79
1Y Return
10.24%
10.24%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.07
23.07
1Y Return
1.81%
1.81%
Buy Reco %
74.19
74.19
TORNTPHARM
PE Ratio
60.36
60.36
1Y Return
22.54%
22.54%
Buy Reco %
75.00
75.00
DRREDDY
PE Ratio
18.88
18.88
1Y Return
0.99%
0.99%
Buy Reco %
55.17
55.17
ZYDUSLIFE
PE Ratio
22.01
22.01
1Y Return
7.25%
7.25%
Buy Reco %
46.43
46.43
WANBURY Forecast
WANBURY Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
WANBURY
WANBURY
Income
Balance Sheet
Cash Flow
Annual Normal View
WANBURY Income Statement
WANBURY Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 523.49 | 447.80 | 400.70 | 451.23 | 394.92 | 589.07 | 500.56 | 604.20 | 603.01 | 603.00 | ||||||||||
Raw Materials | 191.12 | 166.40 | 201.26 | 169.75 | 228.53 | 325.07 | 274.31 | 306.52 | 523.20 | 523.19 | ||||||||||
| Power & Fuel Cost | 18.74 | 15.26 | 14.46 | 15.38 | 17.13 | 18.41 | 20.59 | 24.58 | ||||||||||||
| Employee Cost | 87.77 | 87.32 | 75.89 | 67.48 | 64.15 | 74.81 | 81.00 | 86.92 | ||||||||||||
| Selling & Administrative Expenses | 76.62 | 64.45 | 63.70 | 55.36 | 45.49 | 55.13 | 59.28 | 76.53 | ||||||||||||
| Operating & Other expenses | 41.03 | 105.59 | 20.52 | 36.04 | 19.20 | 2.44 | 41.89 | 11.10 | ||||||||||||
EBITDA | 108.21 | 8.78 | 24.87 | 107.22 | 20.42 | 113.21 | 23.49 | 98.55 | 79.81 | 79.81 | ||||||||||
| Depreciation/Amortization | 10.32 | 10.30 | 9.97 | 9.68 | 9.75 | 11.45 | 12.38 | 13.03 | 13.31 | 13.30 | ||||||||||
| PBIT | 97.89 | -1.52 | 14.90 | 97.54 | 10.67 | 101.76 | 11.11 | 85.52 | 66.50 | 66.51 | ||||||||||
| Interest & Other Items | 35.51 | 30.86 | 39.88 | 32.87 | 23.07 | 20.61 | 21.39 | 29.18 | 36.95 | 36.95 | ||||||||||
| PBT | 62.38 | -32.38 | -24.98 | 64.67 | -12.40 | 81.15 | -10.28 | 56.34 | 29.55 | 29.56 | ||||||||||
| Taxes & Other Items | 0.39 | -0.38 | -0.14 | 0.21 | 0.20 | -0.35 | 0.11 | 0.38 | -0.98 | -0.98 | ||||||||||
| Net Income | 61.99 | -32.00 | -24.84 | 64.46 | -12.60 | 81.50 | -10.39 | 55.96 | 30.53 | 30.54 | ||||||||||
| EPS | 28.71 | -13.63 | -10.47 | 26.46 | -5.04 | 28.26 | -3.18 | 17.10 | 9.32 | 9.33 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
WANBURY Company Updates
FY 2015FY 2015
WANBURY Stock Peers
WANBURY Past Performance & Peer Comparison
WANBURY Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Wanbury Ltd | 30.21 | 32.99 | — |
| Sun Pharmaceutical Industries Ltd | 36.79 | 5.99 | 0.95% |
| Cipla Ltd | 23.07 | 3.89 | 1.06% |
| Torrent Pharmaceuticals Ltd | 60.36 | 16.82 | 0.94% |
WANBURY Stock Price Comparison
Compare WANBURY with any stock or ETFCompare WANBURY with any stock or ETF
WANBURY
WANBURY Holdings
WANBURY Shareholdings
WANBURY Promoter Holdings Trend
WANBURY Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
Lower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
WANBURY Institutional Holdings Trend
WANBURY Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
WANBURY Shareholding Pattern
WANBURY Shareholding Pattern
WANBURY Shareholding History
WANBURY Shareholding History
Foreign Institutions
smallcases containing WANBURY stock
smallcases containing WANBURY stock
Looks like this stock is not in any smallcase yet.
WANBURY Events
WANBURY Events
WANBURY Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
WANBURY has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
WANBURY Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
WANBURY has not given any dividends in last 5 years
WANBURY Upcoming Dividends
WANBURY Upcoming Dividends
No upcoming dividends are available
WANBURY Past Dividends
WANBURY Past Dividends
Cash Dividend
Ex DateEx DateJul 29, 2010
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Jul 29, 2010
WANBURY Stock News & Opinions
WANBURY Stock News & Opinions
Articles & Videos
Spotlight
Wanbury's Patalganga facility receives GMP certification from ANVISA
Earlier this month, on 12 May 2025, the company had also received GMP approval from ANVISA for its Tanuku site in Andhra Pradesh. The certification for the Patalganga site follows ANVISA's review of the inspection report of U.S. FDA, along with other documents submitted by the company. Based on the evaluation, ANVISA granted the GMP certification, confirming the facility's compliance with Brazilian regulatory standards. With this certificate, now both the API manufacturing sites of Wanbury continue to be compliant per ANVISA' s rules & regulations. Wanbury is a pharmaceutical company with a presence in the global API market and domestic branded formulations. The company's consolidated net profit declined 88.12% to Rs 1.22 crore as revenues fell by 8.28% to Rs 133.45 crore in Q3 FY25 as compared with Q3 FY24. The counter declined 1.74% to Rs 299.35 on the BSE. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Wanbury consolidated net profit declines 39.76% in the March 2025 quarter
Net profit of Wanbury declined 39.76% to Rs 20.26 crore in the quarter ended March 2025 as against Rs 33.63 crore during the previous quarter ended March 2024. Sales rose 23.38% to Rs 172.00 crore in the quarter ended March 2025 as against Rs 139.41 crore during the previous quarter ended March 2024. For the full year,net profit declined 45.44% to Rs 30.53 crore in the year ended March 2025 as against Rs 55.96 crore during the previous year ended March 2024. Sales rose 4.14% to Rs 599.51 crore in the year ended March 2025 as against Rs 575.65 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales172.00139.41 23 599.51575.65 4 OPM %17.2313.03 -12.7312.16 - PBDT22.4311.63 93 42.8643.81 -2 PBT19.058.35 128 29.5530.78 -4 NP20.2633.63 -40 30.5355.96 -45 Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Wanbury standalone net profit rises 150.74% in the March 2025 quarter
Net profit of Wanbury rose 150.74% to Rs 20.26 crore in the quarter ended March 2025 as against Rs 8.08 crore during the previous quarter ended March 2024. Sales rose 23.38% to Rs 172.00 crore in the quarter ended March 2025 as against Rs 139.41 crore during the previous quarter ended March 2024. For the full year,net profit rose 0.43% to Rs 30.53 crore in the year ended March 2025 as against Rs 30.40 crore during the previous year ended March 2024. Sales rose 4.14% to Rs 599.51 crore in the year ended March 2025 as against Rs 575.65 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales172.00139.41 23 599.51575.65 4 OPM %17.2313.03 -12.7312.16 - PBDT22.4311.63 93 42.8643.81 -2 PBT19.068.35 128 29.5530.78 -4 NP20.268.08 151 30.5330.40 0 Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Wanbury spurts after Tanuku facility clears ANVISA inspection with zero observations
The inspection was conducted from 16 December to 20 December 2024, confirmed the facility's strict adherence to Current Good Manufacturing Practices (cGMP). As a result, ANVISA has granted the facility the Good Manufacturing Practices (GMP) Certificate. Wanbury is a pharmaceutical company with a presence in the global API market and domestic branded formulations. The company's consolidated net profit declined 88.12% to Rs 1.22 crore as revenues fell by 8.28% to Rs 133.45 crore in Q3 FY25 as compared with Q3 FY24. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Wanbury announces board meeting date
Wanbury will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Wanbury edges higher post conclusion of NCD refinancing at lower rates
The company stated that it has repurchased the entire Rs 95 crore issue of 21% secured NCDs, initially placed in July 2023 with NEO AIF and associates. This repurchase was facilitated through a Rs 175 crore debt refinancing from Emerging India Credit Opportunities Fund II (an associate of Investec Capital Services (India) Pvt. Ltd.). The refinancing offers a significantly reduced interest rate of 12.5% per annum on up to Rs 150 crore of existing debt, covering the Rs 90 crore owed to NEO AIF & associates and Rs 60 crore owed to other lenders. The remaining funds will be used for working capital and capital expenditure to support the company's growth. The repayment of this facility is structured over 5 years, with an average life of 3.25 years and a 9-month moratorium period. Mohan Rayana, whole-time director of Wanbury, said: We're pleased to announce the successful refinancing, underscoring our commitment to financial stability and growth. We're glad to announce the successful refinancing with Emerging India Credit Opportunities Fund II (an associate of Investec Capital Services (India) Pvt. Ltd.), resulting in significant savings in Interest cost. Wanbury is a pharmaceutical company with a presence in the global API market and domestic branded formulations. The company's consolidated net profit declined 88.12% to Rs 1.22 crore as revenues fell by 8.28% to Rs 133.45 crore in Q3 FY25 as compared with Q3 FY24. Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Wanbury consolidated net profit declines 88.12% in the December 2024 quarter
Net profit of Wanbury declined 88.12% to Rs 1.22 crore in the quarter ended December 2024 as against Rs 10.27 crore during the previous quarter ended December 2023. Sales declined 8.28% to Rs 133.45 crore in the quarter ended December 2024 as against Rs 145.50 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales133.45145.50 -8 OPM %10.4514.54 - PBDT4.6213.58 -66 PBT1.2910.26 -87 NP1.2210.27 -88 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Wanbury to declare Quarterly Results
Wanbury will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Wanbury to conduct EGM
Wanbury announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 20 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Wanbury announces board meeting date
Wanbury will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.97%, vs industry avg of 10.2%
Over the last 5 years, market share decreased from 0.18% to 0.15%
Over the last 5 years, net income has grown at a yearly rate of -13.88%, vs industry avg of 20.11%